For results they can feel, prescribe DUPIXENT to target type 2 inflammation, treat OCS-dependent and type 2 asthma patients, and transform their lives with rapid, sustained control... Choose DUPIXENT to open up a world beyond their asthma symptoms.

  1. IL-4 and IL-13, two key and central drivers of type 2 inflammation

  2. TREAT OCS-dependent patients3 & Type 2 asthma patients

  3. TRANSFORM patient lives beyond symptoms
  • 86% of patients reduced or eliminated OCS while maintaining asthma control3,a
  • Up to 550 mL improvement in FEV16,b
  • Up to 75% exacerbation reduction6,c

MAT-BH-2400019/V1/Jan 2024